Infectious Disease
Fungal Infectious Disease
17
Pipeline Programs↗
0
Active Trials↗
14
Companies Involved↗
Fungal Infectious Disease is an emerging landscape with 17 programs across 14 companies. The most active players are Astellas, Otsuka, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 14 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 31
Analysis
Trial Status
1
clinical trials
Unknown status1 · 100%
Clinical Trials
Trial Activity
Population Pharmacokinetics of Fluconazole in the Treatment of Neonatal Fungal Infectious Disease
Unknown status·—·N/A·NCT05775692·150 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)